Articles published by Castle Biosciences, Inc.

Castle Biosciences Reports First Quarter 2023 Results

May 03, 2023

Tickers CSTL

Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

May 03, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

April 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients

April 25, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

April 20, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

April 19, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

March 18, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

March 14, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

March 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results

February 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

February 24, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

February 22, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines

February 09, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

February 07, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

February 01, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023

January 23, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

January 17, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

January 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

November 21, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

November 17, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

November 15, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

November 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Announces Third Quarter 2022 Results

November 02, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences to Present at Upcoming Investor Conferences

November 01, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

October 31, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

October 27, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone

October 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

October 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

Tickers CSTL

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.